Genetic clues to who is at higher risk of dying from prostate cancer
Genetic Predictors of Prostate Cancer Survival
This project looks at inherited genetic differences together with a blood biomarker panel to better spot which men with prostate cancer are more likely to die from the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11258052 on NIH RePORTER |
What this research studies
You will hear about work that combines inherited genetic information with a four-kallikrein blood test to find genes linked to survival after a prostate cancer diagnosis. Researchers will use advanced computer analyses to focus on genes where inherited changes alter gene activity or protein function and relate those changes to how long men live with prostate cancer. The team will analyze genetic data and prior biomarker results from patient samples and large databases to find patterns tied to prostate cancer death. The goal is to develop a genetic risk tool that could help guide screening and treatment decisions for men.
Who could benefit from this research
Good fit: Ideal candidates would be men with prostate cancer or men with elevated PSA levels who are considering further testing or personalized risk information.
Not a fit: Men without prostate cancer, those with unrelated health conditions, or people seeking immediate treatment changes may not gain direct benefit from the research itself.
Why it matters
Potential benefit: If successful, this could help doctors better identify men at real risk of dying from prostate cancer and avoid unnecessary biopsies and treatments for others.
How similar studies have performed: Prior work using the four-kallikrein panel and certain inherited genetic markers has already shown promise in predicting prostate cancer outcomes, and this project builds on those encouraging findings.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Klein, Robert J. — Icahn School of Medicine at Mount Sinai
- Study coordinator: Klein, Robert J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.